Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Expression of estrogen receptor, progesterone receptor, and Her-2/ neu in primary and extra-corporeal endometrial cancer.

Tangjitgamol S, Tanvanich S, Srijaipracharoen S, Manusirivithaya S.

Histol Histopathol. 2013 Jun;28(6):787-94. doi: 10.14670/HH-28.787. Epub 2012 Dec 19.

PMID:
23255089
2.

Expression of ER, PR, and Her-2/neu in endometrial cancer: a clinicopathological study.

Srijaipracharoen S, Tangjitgamol S, Tanvanich S, Manusirivithaya S, Khunnarong J, Thavaramara T, Leelahakorn S, Pataradool K.

Asian Pac J Cancer Prev. 2010;11(1):215-20.

3.

Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.

Huvila J, Talve L, Carpén O, Edqvist PH, Pontén F, Grénman S, Auranen A.

Gynecol Oncol. 2013 Sep;130(3):463-9. doi: 10.1016/j.ygyno.2013.06.015. Epub 2013 Jun 15.

PMID:
23777659
4.
5.

Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.

Halperin R, Zehavi S, Habler L, Hadas E, Bukovsky I, Schneider D.

Eur J Gynaecol Oncol. 2001;22(2):122-6.

PMID:
11446475
6.

Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).

Słodkowska J, Filas V, Buszkiewicz E, Trzeciak P, Wojciechowski M, Koktysz R, Staniszewski W, Breborowicz J, Rojo MG.

Folia Histochem Cytobiol. 2010 Jan 1;48(1):19-25. doi: 10.2478/v10042-010-0015-1.

7.

[Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].

Yao YY, Xu WZ, Wang Y, Shen DH, Wang JL, Wei LH.

Beijing Da Xue Xue Bao Yi Xue Ban. 2011 Oct 18;43(5):743-8. Chinese.

8.

[The value of progesterone and estrogen receptors expression in tissue microarray method in prognosis of patients with endometrioid endometrial cancer].

Gottwald L, Kubiak R, Pasz-Walczak G, Sek P, Piekarski J, Szwalski J, Spych M, Chałubińska-Fendler J, Suzin J, Tyliński W, Jeziorski A.

Ginekol Pol. 2013 Feb;84(2):95-101. Polish.

PMID:
23668054
9.

Simultaneous carcinoma of the endometrium and ovary vs endometrial carcinoma with ovarian metastases: a clinical and immunohistochemical determination.

Halperin R, Zehavi S, Hadas E, Habler L, Bukovsky I, Schneider D.

Int J Gynecol Cancer. 2003 Jan-Feb;13(1):32-7.

PMID:
12631217
10.

HER-2/neu overexpression and hormone dependency in endometrial cancer: analysis of cohort and review of literature.

Mariani A, Sebo TJ, Katzmann JA, Riehle DL, Dowdy SC, Keeney GL, Lesnick TG, Podratz KC.

Anticancer Res. 2005 Jul-Aug;25(4):2921-7. Review.

11.

Her-2/neu status: a neglected marker of prognostication and management of breast cancer patients in India.

Zubeda S, Kaipa PR, Shaik NA, Mohiuddin MK, Vaidya S, Pavani B, Srinivasulu M, Latha MM, Hasan Q.

Asian Pac J Cancer Prev. 2013;14(4):2231-5.

12.

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.

Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ.

J Natl Cancer Inst. 2003 Jan 15;95(2):142-53.

PMID:
12529347
13.

Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.

Nyagol J, Nyong'o A, Byakika B, Muchiri L, Cocco M, de Santi MM, Spina D, Bellan C, Lazzi S, Kostopoulos I, Luzi P, Leoncini L.

Anal Quant Cytol Histol. 2006 Apr;28(2):97-103.

PMID:
16637512
14.

Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.

Ferrandina G, Ranelletti FO, Gallotta V, Martinelli E, Zannoni GF, Gessi M, Scambia G.

Gynecol Oncol. 2005 Sep;98(3):383-9.

PMID:
15979129
15.

[Correlation between receptor status and results of treatment in endometrial carcinoma].

Baĭnazarova AA, Iskakova ZhK.

Vopr Onkol. 2006;52(6):654-8. Russian.

PMID:
17338243
16.

Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.

Høgdall EV, Christensen L, Høgdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK.

Oncol Rep. 2007 Nov;18(5):1051-9.

PMID:
17914554
17.

Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.

Sharif MA, Mamoon N, Mushtaq S, Khadim MT.

J Coll Physicians Surg Pak. 2009 Feb;19(2):99-103. doi: 02.2009/JCPSP.99103.

PMID:
19208313
18.

Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer.

Rahman MT, Nakayama K, Ishikawa M, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Iida K, Miyazaki K.

Oncology. 2013;84(3):166-73. doi: 10.1159/000342967. Epub 2013 Jan 9.

PMID:
23306391
19.

[Effectiveness of tissue microarray technique for the assessment of estrogen and progesterone receptors expression in endometrioid endometrial cancer--preliminary report].

Gottwald L, Sek P, Kubiak R, Pasz-Walczak G, Piekarski J, Szwalski J, Suzin J, Tyliński W, Hendzel K, Jeziorski A.

Ginekol Pol. 2012 May;83(5):342-6. Polish.

PMID:
22708330
20.

Supplemental Content

Support Center